Gossamer Bio (NASDAQ:GOSS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen upgraded Gossamer Bio (NASDAQ:GOSS) from a "sell" to a "hold" rating. Other analysts have also commented positively, with Wedbush raising the target price from $4.00 to $5.00 and maintaining an "outperform" rating. Gossamer Bio's stock opened at $2.36, with a market cap of $546.25 million. The company reported a revenue of $13.29 million for the last quarter, exceeding estimates. Institutional investors hold 81.23% of the stock. Gossamer Bio focuses on developing treatments for pulmonary arterial hypertension.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.
A number of other analysts also recently commented on the company. Wedbush boosted their target price on Gossamer Bio from $4.00 to $5.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 6th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Gossamer Bio in a research report on Thursday, September 11th. Scotiabank started coverage on shares of Gossamer Bio in a research note on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price objective on the stock. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Gossamer Bio in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $8.50.
Check Out Our Latest Report on Gossamer Bio
Gossamer Bio Stock Up 2.2%
Shares of NASDAQ GOSS opened at $2.36 on Friday. The stock has a market capitalization of $546.25 million, a price-to-earnings ratio of -3.42 and a beta of 1.85. Gossamer Bio has a 52 week low of $0.66 and a 52 week high of $3.60. The firm has a 50-day moving average price of $2.61 and a 200 day moving average price of $1.87.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%.The company had revenue of $13.29 million for the quarter, compared to analyst estimates of $6.32 million. Equities research analysts expect that Gossamer Bio will post -0.28 EPS for the current fiscal year.
Hedge Funds Weigh In On Gossamer Bio
Several hedge funds and other institutional investors have recently modified their holdings of GOSS. Drive Wealth Management LLC increased its position in Gossamer Bio by 52.7% during the 2nd quarter. Drive Wealth Management LLC now owns 25,474 shares of the company's stock worth $31,000 after purchasing an additional 8,797 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Gossamer Bio by 136.7% during the third quarter. Jones Financial Companies Lllp now owns 17,360 shares of the company's stock worth $47,000 after buying an additional 10,027 shares during the period. Ciovacco Capital Management LLC acquired a new stake in shares of Gossamer Bio in the third quarter worth $27,000. Brighton Jones LLC purchased a new position in shares of Gossamer Bio in the 3rd quarter valued at $36,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of Gossamer Bio during the 3rd quarter valued at $48,000. 81.23% of the stock is owned by institutional investors and hedge funds.
Gossamer Bio Company Profile
(Get Free Report)Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
Further Reading
- Five stocks we like better than Gossamer Bio
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- 2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail
- How to start investing in penny stocks
- CrowdStrike Partners With CoreWeave But Investors Sell the News
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Gossamer Bio Right Now?
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
